Merck
No price chart data available for 1D timeframe.
Rating
Why Price Moved
Shares are trading higher after the company report...
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broa...
Latest News
11 hours ago · fool.com
Is Merck's Stock Still a Good Buy at $150?Merck is coming off a strong quarter as revenue from a new version of Keytruda boosted its top line. It remains likely, however, that its revenue will drop off in the near future as key patents on Keytruda are expiring in the near future.
2 days ago · 247wallst.com
He Has Had Surgery for Melanoma and Is Terrified the Cancer Will Return. A New Vaccine Kept 82% of Trial Patients Cancer-Free for Two Years, but Medicare Won’t Pay for Experimental TreatmentA retiree on Original Medicare finishes melanoma surgery and hears about a personalized vaccine that could cut his odds of relapse. Whether he can get it, and who pays for what, hinges on a little-known coverage rule.
3 days ago · businesswire.com
Merck Receives Positive EU CHMP Opinion to Expand Marketing Authorization for ENFLONSIA® (clesrovimab) to Include Children Up to 24 Months of Age Who Remain Vulnerable to Severe RSV Disease Through Their Second RSV SeasonRAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the approval of an expanded indication for ENFLONSIA® (clesrovimab) to include prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in children up to 24 months of age at increased risk for severe RSV dis.
3 days ago · businesswire.com
Merck Receives Positive EU CHMP Opinion for WELIREG® (belzutifan) in Combination With Lenvatinib for Adults With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC) Following Treatment With an Anti-PD-1/PD-L1 TherapyRAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending approval of WELIREG® (belzutifan), Merck's first-in-class oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, plus lenvatinib, the orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, for the treatment of adult p.
4 days ago · marketbeat.com
What Merck KGaA (MRK) Said on Its Q3 Earnings CallMerck KGaA ETR: MRK raised its full-year 2026 outlook for the third time after faster third-quarter sales growth in its Life Science and Electronics businesses offset pressure on its Healthcare portfolio.
6 days ago · businesswire.com
FDA Approves PIMJETMI® (pimicotinib) for Patients with Tenosynovial Giant Cell TumorDARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, announced today that the U.S. Food and Drug Administration (FDA) has approved PIMJETMI® (pimicotinib), a once-daily oral colony stimulating factor-1 receptor (CSF-1R) inhibitor, as a systemic treatment for adults with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection may cause worsening functional limitation or severe morbidity. “People living with TGCT have long faced difficult tre.
8 days ago · businesswire.com
Merck Announces Positive Results from Phase 2b Trial of Efinopegdutide in Adults with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Stage 2-3 FibrosisRAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the presentation of positive results from the company's Phase 2b clinical trial that evaluated the safety and efficacy of three doses of once-weekly, subcutaneous efinopegdutide (4 mg, 7 mg and 10 mg), an investigational injectable GLP-1/glucagon receptor co-agonist, versus placebo for the treatment of adults with MASH and stage F2 or F3 liver fibrosis. The findings were prese.
8 days ago · zacks.com
MRK's 2027 Outlook Challenging, Long-Term Prospects PromisingMerck's 2027 growth faces generic pressures, vaccine weakness and Keytruda slowdown, but its expanding pipeline offers promising long-term potential.
9 days ago · 247wallst.com
Two 70-Year-Olds Will Start the Same $12,272 Keytruda Qlex Cancer Injections. One With Medigap Plan G Will Owe $0 in Coinsurance After the Part B Deductible, While the Other Will Owe 20% With No Annual CapTwo men start the same one-minute cancer shot on the same day, yet their Medicare bills will diverge sharply. A hidden enrollment deadline, likely missed years ago, may decide who pays and who doesn't.
10 days ago · zacks.com
Merck Stock Shows Sustained Strength: Time to Buy, Sell or Hold?MRK's growth momentum faces patent and competitive risks as Keytruda demand and new launches support growth.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove MRK